Neuroprotective Effects of Vitamin D in Multiple Sclerosis

Download Download as PDF (Size:317KB)  HTML   XML  PP. 198-207  
DOI: 10.4236/nm.2011.23027    4,589 Downloads   10,485 Views   Citations

ABSTRACT

Multiple sclerosis (MS), an autoimmune and neurodegenerative disease with no available cure, is marked by both physical and cognitive disability. In MS, central nervous system white matter lesions, believed to be consequences of inappropriate immune system reactivity, compromise inter-neuronal communication and, depending on the location of damage, beget a variety of symptoms including fatigue, loss of sensation, weakness of limbs, slowed psychomotor processing, and impaired memory. Recently, low vitamin D levels have been identified as a potential risk factor for MS, precipitating research into the immunomodulating properties of this vitamin that allow it to work in both a protective and therapeutic manner. Despite its promise as a disease-modifying agent, however, there is scant research that looks explicitly at vitamin D levels and cognitive symptoms of MS. Given the cognitive enhancing effects of vitamin D in other chronic inflammatory conditions such as chemotherapy-induced cognitive dysfunction and Alzheimer’s disease, there is urgent need to research whether vitamin D may prove equally beneficial in reducing cognitive sequelae in MS. Guidelines for future research are suggested.

Cite this paper

M. Cadden, N. Koven and M. Ross, "Neuroprotective Effects of Vitamin D in Multiple Sclerosis," Neuroscience and Medicine, Vol. 2 No. 3, 2011, pp. 198-207. doi: 10.4236/nm.2011.23027.

References

[1] R. G. Frank and T. R. Elliot, “Handbook of Rehabilitation Psychology,” American Psychological Association, Wa- shington D.C., 2000. doi:10.1037/10361-000
[2] D. E. McFarlin and H. F. McFarland, “Multiple Sclerosis (First of Two Parts),” New England Journal of Medicine, Vol. 307, No. 19, 1982, pp. 1183-1188. doi:10.1056/NEJM198211043071905
[3] Canadian Burden of Illness Study Group, “Burden of Illness of Multiple Sclerosis: Part 1. Cost of Illness,” Canadian Journal of Neurological Sciences, Vol. 25, 1988, pp. 23-30.
[4] National Institute of Health, “NINDS Multiple Sclerosis Information Page,” 2010. http://www.nids.nih.gov/disor- ders/multiple_sclerosis.
[5] M. Sospedra and R. Martin, “Immunology of Multiple Sclerosis,” Annual Review of Immunology, Vol. 23, 2005, pp. 683-747. doi:10.1146/annurev.immunol.23.021704.115707
[6] J. L. Haines, H. A. Terwedow, K. Burgess, M. A. Pericak-Vance, J. B. Rimmler, E. R. Martin, J. R. et al., “Linkage of the MHC to Familial Multiple Sclerosis Su- ggests Genetic Heterogeneity,” Human Molecular Genetics, Vol. 7, No. 8, 1998, pp. 1229-1234. doi:10.1093/hmg/7.8.1229
[7] J. Hillert and O. Olerup, “HLA and MS,” Neurology, Vol. 43, 1993, pp. 2426-2427.
[8] C. Bjartmar, J. R. Wujek and B. D. Trapp, “Axonal Loss in the Pathology of MS: Consequences for Understanding the Progressive Phase of the Disease,” Journal of the Neurological Sciences, Vol. 206, No. 2, 2003, pp. 165-171. doi:10.1016/S0022-510X(02)00069-2
[9] A. M. Parry, R. B. Scott, J. Palace, S. Smith and P. M. Matthews, “Potentially Adaptive Functional Changes in Cognitive Processing for Patients with Multiple Sclerosis and Their Acute Modulation by Rivastigmine,” Brain, Vol. 126, No. 12, 2003, pp. 2750-2760. doi:10.1093/brain/awg284
[10] M. Kerschensteiner, M.E. Schwab, J.W. Lichtman and T. Misgeld, “In Vivo Imaging of Axonal Degeneration and Regeneration in the Injured Spinal Cord,” Nature Medi- cine, Vol. 11, No. 5, 2005, pp. 572-577. doi:10.1038/nm1229
[11] C. Bjartmar, G. Kidd, S. Mork, R. Rudick and B. D. Trapp, “Neurological Disability Correlates with Spinal Cord Ax- onal Loss and Reduced N-acetyl Aspartate in Chronic Multiple Sclerosis Patients,” Annals of Neurology, Vol. 48, No. 6, 2000, pp. 893-901. doi:10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B
[12] R. Dutta and B. D. Trapp, “Pathogenesis of Axonal and Neuronal Damage in Multiple Sclerosis,” Neurology, Vol. 68, Suppl 3, 2007, pp. S22-S31. doi:10.1212/01.wnl.0000275229.13012.32
[13] M. Filippi, C. Tortorella, M. Rovaris, M. Bozzali, F. Possa, M.P. Sormani, et al., “Changes in the Normal Appearing Brain Tissue and Cognitive Impairment in Multiple Sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 68, No. 2, 2000, pp. 157-161. doi:10.1136/jnnp.68.2.157
[14] K. M. Myhr, “Vitamin D Treatment in Multiple Sclero- sis,” Journal of Neurological Sciences, Vol. 286, No. 1-2, 2009, pp. 104-108. doi:10.1016/j.jns.2009.05.002
[15] T. Y. McDowell, S. Amr, P. Langenberg, W. Royal and C. Bever, “Time of Birth, Residential Solar Radiation, and Age at Onset of Multiple Sclerosis,” Neuroepidemiology, Vol. 34, No. 4, 2010, pp. 238-244. doi:10.1159/000297749
[16] J. Correale, M. C. Ysrraelit and M. I. Gaitán, “Immuno- modulatory Effects of Vitamin D in Multiple Sclerosis,” Brain, Vol. 132, 2009, pp. 1146-1160. doi:10.1093/brain/awp033
[17] J. Smolders, J. Damoiseaux, P. Menheere and R. Hup- perts, “Vitamin D as an Immune Modulator in Multiple Sclerosis: A Review,” Journal of Neuroimmunology, Vol. 194, No. , 2008, pp. 7-17. doi:10.1016/j.jneuroim.2007.11.014
[18] T. C. Stamp and J. M. Round, “Seasonal Changes in Hu- man Plasma Levels of 25 Hydroxyvitamin D,” Nature, Vol. 247, No. 442, 1974, pp. 563-565. doi:10.1038/247563a0
[19] D.P. Auer, E.M. Schumann, T. Kumpfel, C. Gossl and C. Trenkwalder, “Seasonal Fluctuations of Gadolinium-En- hancing Magnetic Resonance Imaging Lesions in Multi- ple Sclerosis,” Annals of Neurology, Vol. 47, 2000, pp. 276-277. doi:10.1002/1531-8249(200002)47:2<276::AID-ANA28>3.0.CO;2-1
[20] A. F. Embry, L. R. Snowdon and R. Veith, “Vitamin D and Seasonal Fluctuations of Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis,” Annals of Neurology, Vol. 48, No. 2, 2000, pp. 271- 272. doi:10.1002/1531-8249(200008)48:2<271::AID-ANA28>3.0.CO;2-O
[21] J. Salzer, A. Svenningson and P. Sundstorm, “Season of Birth and Multiple Sclerosis in Sweden,” Acta Neu- rologica Scandinavica, Vol. 121, No. 1, 2010, pp. 20-23. doi:10.1111/j.1600-0404.2009.01181.x
[22] J. Verhaeghe and R. Bouillon, “Calciotropic Hormones during Reproduction,” Journal of Steroid Biochemistry and Molecular Biology, Vol. 41, No. 3-8, 1992, pp. 469-477. doi:10.1016/0960-0760(92)90372-P
[23] J.A. Frith and J. G. McLeod, “Pregnancy and Multiple Sclerosis,” Journal of Neurology, Neurosurgery, and Psy- chiatry, Vol. 51, 1998, pp. 495-498. doi:10.1136/jnnp.51.4.495
[24] M. Soilu-Hanninen, M. Laaksonen, I. Laitinen, J. P. Er- alinna, E. M. Lilius and I. A. Mononen, “Longitudinal Study of Serum 25-hydroxyvitamin D and Intact PTH Levels Indicate the Importance of Vitamin D and Calcium Homeostasis Regulation in Multiple Sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 79, No. 2, 2008, pp. 152-157. doi:10.1136/jnnp.2006.105320
[25] K. L. Munger, S. M. Zhang, E. O’Reilly, M. A. Hernán, M. J. Olek, W. C. Willett and A. Ascherio, “Vitamin D In- take and Incidence of Multiple Sclerosis,” Neurology, Vol. 62, No. 1, 2004, pp. 60-65.
[26] K. L. Munger, L. I. Levin, B. W. Hollis, N. S. Howards and A. Ascherio, “Serum 25 Hydroxyvitamin D Levels and Risk of Multiple Sclerosis,” Journal of the American Medical Association, Vol. 296, No. 23, 2006, pp. 2832- 2838. doi:10.1001/jama.296.23. 2832
[27] J. M. Burton, S. M. Kimball, R. Veith, A. Bar-Or, H. M. Dosch, L. Thibault, et al., “A Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis,” Multiple Sclerosis, Vol. 14, Suppl 1, 2008, p. 34.
[28] M. T. Cantorna, C. E. Hayes and H. F. DeLuca, “1,25- hydroxyvitamin D3 Reversibly Blocks the Progression of Relapsing Encephalomyelitis: A Model of Multiple Scle- rosis,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, 1996, pp. 7861-7864. doi:10.1073/pnas.93.15.7861
[29] C. M. Veldman, M. T. Cantorna and H. F. DeLuca, “Ex- pression of 1,25(OH)2 D3 Receptors in the Immune Sys- tem,” Biochemical Biophysiology, Vol. 374, No. 2, 2000, pp. 334-339. doi:10.1006/abbi.1999.1605
[30] D. M. Provvendini, C. D. Tsoukas, L. J. Deftos and S. C. Manolagas, “1,25(OH)2 D3 Receptors in Human Leuko- cytes,” Science, Vol. 221, No. 4616, 1983, pp. 1181-1183. doi:10.1126/science.6310748
[31] K.C. Simon, K.L. Munger, L. Xing and A. Ascherio, “Polymorphisms in Vitamin D Metabolism Related Genes and Risk of Multiple Sclerosis,” Multiple Sclerosis, Vol. 16, No. 2, 2010, pp. 133-138. doi:10.1177/1352458509355069
[32] T. Fukazawa, I. Yabe, S. Kikuchi, H. Sasaki, T. Hamada, K. Miyasaka, et al., “Association of Vitamin D Receptor Gene Polymorphism with Multiple Sclerosis in Japanese,” Journal of the Neurological Sciences, Vol. 166, 1999, pp. 47-52. doi:10.1016/ S0022-510X(99)00112-4
[33] R.M. Ruggieri, R. Palermo, G. Vitello, M. Gennuso, N. Settipani and F. Piccoli, “Cognitive Impairment in Pa- tients Suffering from Relapsing-Remitting Multiple Scle- rosis with EDSS < or = 3.5,” Acta Neurologica Scandi- navica, Vol. 108, No. 5, 2003, pp. 323-326. doi:10.1034/j.1600-0404.2003.00157.x
[34] W. W. Beatty, C. R. Blanco, S. L. Wilbanks, R. H. Paul and K. A. Hames, “Demographic, Clinical, and Cognitive Characteristics of Multiple Sclerosis Patients Who Con- tinue to Work,” Journal of Neurologic Rehabilitation, Vol. 9, No. 3, 1995, pp. 167-173. doi:10.1177/154596839500900306
[35] S. A. Morrow, A. Drake, R. Zivadinov, F. Munschauer, B. Weinstock-Guttman and R. H. B. Benedict, “Predicting Loss of Employment Over Three Years in Multiple Scle- rosis: Clinically Meaningful Cognitive Decline,” The Clinical Neuropsychologist, Vol. 24, No. 7, 2010, pp. 1131-1145. doi:10.1080/ 13854046.2010.511272
[36] H. R. Kessler, R. A. Cohen, K. Lauer and D. F. Kausch, “The Relationship Between Disability and Memory Dys- function in Multiple Sclerosis,” International Journal of Neuroscience, Vol. 62, No. 1-2, 1992, pp. 17-34. doi:10.3109/00207459108999754
[37] E. A. Hakim, A. M. Bakheit, T. N. Bryant, M. W. Roberts, S. A. McIntosh-Michaelis, A. J. Spackman, et al., “The Social Impact of Multiple Sclerosis—A Study of 305 Pa- tients and Their Relatives,” Disability and Rehabilitation, Vol. 22, No. 6, 2000, pp. 288-293. doi:10.1080/096382800296755
[38] S. M. Rao, G. J. Leo, L. Ellington, T. Nauertz, L. Bernar- din and F. Unverzagt, “Cognitive Dysfunction in Multiple Sclerosis. II. Impact on Employment and Social Func- tioning,” Neurology, Vol. 41, No. 5, 1991, pp. 692-696.
[39] S. M. Rao, “Neuropsychological Aspects of Multiple Sclerosis,” In: C. S. Raine, H. F. McFarland, and W. W. Tourtellote, Eds., Multiple Sclerosis: Clinical and Patho- genic Basis, Chapman & Hall, London, 1997, pp. 357-362.
[40] J. M. Bruce and P. A. Arnett, “Self-Reported Everyday Memory and Depression in Patients with Multiple Scle- rosis,” Journal of Clinical and Experimental Neuropsy- chology, Vol. 26, No. 2, 2004, pp. 200-214. doi:10.1076/jcen.26.2.200.28081
[41] A. E. Thornton and N. Raz, “Memory Impairment in Multiple Sclerosis: A Quantitative Review,” Neuropsychology, Vol. 11, No. 3, 1997, pp. 357-366. doi:10.1037/0894-4105.11.3.357
[42] S. M. Rao, “Neuropsychology of Multiple Sclerosis: A Critical Review,” Journal of Clinical and Experimental Neuropsychology, Vol. 8, No. 5, 1986, pp. 503-542. doi:10.1080/01688638608405173
[43] K. K. Zakzanis, “Distinct Neurocognitive Profiles in Mul- tiple Sclerosis Subtypes,” Archives of Clinical Neuro- psychology, Vol. 15, No. 2, 2000, pp. 115-136.
[44] F. Patti, C. Leone and E. D’Amico, “Treatment Options of Cognitive Impairment in Multiple Sclerosis,” Neuro- logical Science, Vol. 31, Suppl 2, 2010, pp. S265-S269. doi:10.1007/s10072-010-0438-7
[45] M.K. Tuxen and S.W. Hansen, “Neurotoxicity Secondary to Antineoplastic Drugs,” Cancer Treatment Reviews, Vol. 20, No. 2, 1994, pp. 191-214. doi:10.1016/0305-7372(94)90027-2
[46] L. Troy, K. McFarland, S. Littman-Power, B.J. Kelly, E.T. Walpole, D. Wyld, et al., “Cisplatin-Based Therapy: A Neurological and Neuropsychological Review,” Psycho- Oncology, Vol. 9, No. 1, 2000, pp. 29-39. doi:10.1002/(SICI)1099-1611(200001/02)9:1<29::AID-PON428>3.0.CO;2-Z
[47] A. J. Saykin, T. A. Ahles and B. C. McDonald, “Mecha- nisms of Chemotherapy-Induced Cognitive Disorders: Neuropsychological, Pathophysiological, and Neuroi- maging Perspectives,” Seminars in Clinical Neuropsy- chiatry, Vol. 8, 2003, pp. 201-216.
[48] B. Collins, J. Mackenzie, A. Stewart, C. Bielajew and S. Verma, “Cognitive Effects of Chemotherapy in Post- Menopausal Breast Cancer Patients 1 Year after Treat- ment,” Psycho-Oncology, Vol. 18, No. 2, 2009, pp. 134- 143. doi:10.1002/pon.1379
[49] H. S. Jim, K. A. Donovan, B. J. Small, M. A. Andrykowski, P. N. Munster and P. B. Jacobsen, “Cognitive Functioning in Breast Cancer Survivors: A Controlled Comparison,” Cancer, Vol. 115, No. 8, 2009, pp. 11776- 11783. doi:10.1002/cncr.24192
[50] J. Vardy, J. S. Wefel, T. Ahles, I. F. Tannock and S. B. Schagen, “Cancer and Cancer-Therapy Related Cognitive Dysfunction: An International Perspective from the Ven- ice Cognitive Workshop,” Annals of Oncology, Vol. 19, No. 4, 2008, pp. 623-629. doi:10.1093/annonc/mdm500
[51] M. H. Weineke and E. R. Dienst, “Neuropsychological Assessment of Cognitive Functioning Following Chemo- therapy for Breast Cancer,” Psycho-Oncology, Vol. 4, No. 1, 1995, pp. 61-66. doi:10.1002/pon.2960040108
[52] L. A. Ouimet, A. Stewart, B. Collins, D. Schindler and C. Bielajew, “Measuring Neuropsychological Change Fol- lowing Breast Cancer Treatment: An Analysis of Statisti- cal Models,” Journal of Clinical and Experimental Neu- ropsychology, Vol. 31, 2009, pp. 73-89. doi:10.1080/13803390801992725
[53] C. B. Simone, N. L. Simone and C. B. Simone II, “Nutri- tional and Lifestyle Modification to Augment Oncology Care: An overview,” Journal of Orthomolecular Medicine, Vol. 12, No. 4, 1997, pp. 197-206.
[54] C. Oudshoorn, F. U. S. Mattace-Raso, N. van der Velde, E. M. Colin and T. J. M. van der Cammen, “Higher Serum Vitamin D3 Levels are Associated with Better Cognitive Test Performance in Patients with Alzheimer’s Disease,” Dementia and Geriatric Cognitive Disorders, Vol. 25, No. 6, 2008, pp. 539-543. doi:10.1159/000134382
[55] C. H. Wilkins, Y. I. Sheline, C. M. Roe, S. J. Birge and J. C. Morris, “Vitamin D Deficiency Is Associated with Low Mood and Worse Cognitive Performance in Older Adults,” American Journal of Geriatric Psychiatry, Vol. 14, No. 12, 2006, pp. 1032-1040. doi:10.1097/01.JGP.0000240986.74642.7c
[56] C. Annweiler, A. M. Schott, Y. Rolland, H. Blain, F. R. Hermann and O. Beauchet, “Dietary Intake of Vitamin D and Cognition in Older Women: A Large Population- Based Study,” Neurology, Vol. 75, No. 20, 2010, pp. 1810-1816. doi:10.1212/WNL. 0b013e3181fd6352
[57] R. J. Przybelski and N. C. Binkley, “Is Vitamin D Impor- tant for Preserving Cognition? A Positive Correlation of Serum 25-Hydroxyvitamin D Concentration with Cogni- tive Function,” Archives of Biochemistry and Biophysics, Vol. 460, No. 2, 2007, pp. 202-205. doi:10.1016/j.abb.2006.12.018
[58] D. J. Llewellyn, I. A. Lang, K. M. Langa, G. Muniz-Terrera, C. L. Phillips, A. Cherubini, et al., “Vitamin D and Risk of Cognitive Decline in Elderly Persons,” Archives of Internal Medicine, Vol. 170, No. 13, 2010, pp. 1135-1141. doi:10.1001/archinternmed.2010.173
[59] S. Moritz, S. Ferahli and D. Naber, “Memory and Atten- tion Performance in Psychiatric Patients: Lack of Corre- spondence between Clinician-Rated and Patient-Rated Functioning with Neuropsychological Test Results,” Journal of the International Neuropsychological Society, Vol. 10, 2004, pp. 623-633. doi:10.1017/S1355617704104153
[60] R. M. Roth, P. K. Isquith and G. A. Gioia, “Behavior Rating Inventory of Executive Function-Adult Version,” Psychological Assessment Resources, Lutz, 2005.
[61] R. H. Paul, W. W. Beatty, R. Schneider, C. R. Blanco and K. A. Hames, “Cognitive and Physical Fatigue in Multiple Sclerosis: Relations between Self-Report and Objective Performance,” Applied Neuropsychology, Vol. 5, No. 3, 1998, pp. 143-148. doi:10.1207/s15324826an0503_5
[62] A. H. Kizilbash, R. D. Vanderploeg and G. Curtiss, “The Effects of Depression and Anxiety on Memory Perform- ance,” Archives of Clinical Neuropsychology, Vol. 17, No. 1, 2002, pp. 57-67.
[63] S. N. Young, “Has the Time Come for Clinical Trials on the Antidepressant Effects of Vitamin D?” Journal of Psychiatry and Neuroscience, Vol. 34, No. 1, 2009, p. 3.
[64] J.L. Steckley, D.A. Dyment, A.D. Sadovnick, N. Risch, C. Hayes and G.C. Ebers, “Genetic Analysis of Vitamin D Related Genes in Canadian Multiple Sclerosis Patients,” Neurology, Vol. 54, No. 3, 2000, pp. 729-732.

  
comments powered by Disqus
  • ADVERTISEMENT

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.